{"symbol":"BMY","fiscalQuarter":"Q2-2026","reportDate":"2026-07-30","reportTime":"BMO","status":"upcoming","company":{"name":"Bristol-Myers Squibb Company","sector":"Health Care","industry":"Pharmaceuticals"},"tier":"free","webUrl":"https://earningsnxt.ai/ticker/BMY/earnings/Q2-2026","preBrief":{"companySnapshot":"Bristol-Myers Squibb Company (BMY) is a leading global biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for patients with serious diseases. As part of the Health Care sector, it plays a crucial role in addressing unmet medical needs, particularly in oncology, immunology, and cardiovascular diseases.","keyMetrics":[{"name":"Earnings Per Share (EPS)","why":"EPS is a key indicator of profitability and will show how well the company is managing its costs and revenues.","consensus":"N/A"},{"name":"Revenue Growth","why":"Revenue growth is essential to assess the company's ability to expand its market presence and product offerings.","consensus":"N/A"},{"name":"Pipeline Updates","why":"Updates on drug development and pipeline progress can significantly impact investor sentiment and future revenue potential.","consensus":"N/A"}],"lastQuarterRecap":{"summary":"In Q1-2026, Bristol-Myers Squibb reported an EPS of $1.58, exceeding expectations by 9.65%. The stock reacted positively, gaining 5.21% the following day.","promises":["Continue to advance key pipeline candidates.","Focus on improving operational efficiency.","Commit to enhancing shareholder value."]},"wallStreetExpectations":{"summary":"Investors are cautiously optimistic ahead of the earnings report, given the company's strong history of beating EPS estimates. However, concerns about revenue growth and pipeline developments linger.","bullCase":"If Bristol-Myers Squibb can deliver strong EPS and positive updates on its drug pipeline, it could lead to significant stock appreciation.","bearCase":"Conversely, if the company fails to meet EPS expectations or provides disappointing updates on its pipeline, it could result in a sharp decline in stock price."},"optionsSignal":{"impliedMove":"4.83%","context":"The options market is pricing in a move of about 4.83%, indicating that traders expect some volatility around the earnings announcement."},"earningsTrackRecord":[{"quarter":"Q1-2026","epsSurprise":"+9.65%","reaction":"+5.21%"},{"quarter":"Q4-2025","epsSurprise":"+9.28%","reaction":"+3.30%"},{"quarter":"Q3-2025","epsSurprise":"+10.14%","reaction":"+7.09%"},{"quarter":"Q2-2025","epsSurprise":"-12.63%","reaction":"-5.81%"},{"quarter":"Q1-2025","epsSurprise":"+19.52%","reaction":"+0.33%"}],"pivotalQuestions":[{"question":"What will be the EPS for Q2-2026?","whyItMatters":"Given the company's strong history of EPS surprises, this number will be critical in determining market sentiment."},{"question":"What updates will be provided on the drug pipeline?","whyItMatters":"Investors will closely watch for any advancements or setbacks in the pipeline, as these can significantly affect future revenue."}],"thesisBreakLevels":{"bullTrigger":"An EPS of $1.70 or higher would confirm strong operational performance and investor confidence.","bearTrigger":"An EPS below $1.40 would raise concerns about profitability and future growth.","context":"The market is debating whether Bristol-Myers Squibb can maintain its strong earnings trajectory amidst competitive pressures and pipeline challenges."},"scenarioPlaybook":{"beatAndRaise":"If Bristol-Myers Squibb beats EPS expectations, history suggests a potential stock increase of around 4.21%, confirming the bullish outlook.","inLineCautious":"If results are in line with expectations, the stock may see muted movement as investors await further guidance.","miss":"A miss on EPS could lead to a decline of about 5.81%, reflecting disappointment in the company's performance."},"peerReadThroughs":[],"setupPatternInsight":{"pattern":"Prior-quarter beat + options rich in Health Care","sampleSize":30,"fadeRate":"13 of 29 (45%)","insight":"This setup has occurred 30 times across Health Care in the last 2 years. 13 of 29 faded and 16 held \u2014 no strong directional bias after the initial reaction. The average absolute 1-day move is 5.5%, with a raw directional average of +2.9% (modestly positive historical bias)."},"whatTheStreetIsMissing":{"thesis":"The Street may be underestimating the potential for Bristol-Myers Squibb's pipeline to deliver unexpected results, particularly in oncology.","supportingPoints":["The company has a strong track record of exceeding EPS estimates, with an 88% beat rate over the last eight quarters.","Options pricing suggests a relatively low expected move compared to historical averages, indicating potential for a larger surprise."],"riskToConsensus":"If pipeline updates reveal significant advancements, it could shift investor sentiment dramatically."},"whatToListenFor":["Any commentary on the performance of key drugs in the pipeline.","Updates on regulatory approvals or clinical trial results.","Management's outlook on revenue growth for the upcoming quarters.","Insights into cost management strategies and operational efficiency.","Any changes in guidance or strategic priorities."],"metaDescription":"Bristol-Myers Squibb (BMY) reports Q2 2026 earnings on July 30. Investors are watching for EPS and pipeline updates."}}